Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Adam Bates


DPhil Student

Characterising CD8+ T Cell Responses in Non-Small-Cell Lung Cancer


Before joining the Dong group, I completed my BSc in Biomedical Sciences with a Year in Industry at the University of York, obtaining First-Class Honours with Distinction. For my final-year project, I was involved with investigating the potential role of RNA methylation in the upregulation of PD-L1 as part of the Lagos group. I spent a year working in GlaxoSmithKline's BioPharm Discovery department where I investigated next-generation bispecific antibody formats with potential oncological applications and published my first paper (albeit a review).

Research interests

My research in the Dong group is focused on characterising and understanding CD8+ T cell responses in the NSCLC microenvironment at a single-cell resolution, using a combination of ex vivo scRNA/TCR-seq and paired in vitro expanded T cell clones. We are especially interested in tumor-reactive clonotypes that lack expression of the inhibitory receptor PD-1, or are specific for 'Cancer Testis Antigens', hypothesising that these two populations will overlap. We hope to identify a population of tumour-reactive TILs that lack canonical markers of exhaustion ex vivo yet display high cytotoxic and proliferative capabilities in vitro, suggesting the potential to mediate tumour control. Such a population may have improved therapeutic outcome when used for adoptive cell transfer compared to non-specifically expanded TILs, analogous to CD69- CD39- TILs described by the Rosenberg group (Krishna et al, 2021), and act as a prognostic marker and predictor of response to immune checkpoint blockade, similar to the TCF-1+ 'progenitor exhausted' CD8+ T cells in melanoma recently described by several groups (Feldman et al, 2018; Siddiqui et al, 2019; Li et al, 2019; Chen et al 2019).

Recent publications

More publications